

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of

Meltzer et al.

Date of Deposit: August 21, 1998

For: AIB1, A NOVEL STEROID
RECEPTOR COACTIVATOR

Date: August 21, 1998

CERTIFICATE OF MAILING

I HEREBY CERTIFY THAT THIS PAPER AND THE DOCUMENTS REFERRED TO AS BEING ATTACHED OR ENCLOSED HERewith ARE BEING DEPOSITED WITH THE UNITED STATES POSTAL SERVICE ON August 21, 1998 AS EXPRESS MAIL NO. EM295379309US IN AN ENVELOPE ADDRESSED TO: BOX PCT, ASSISTANT COMMISSIONER FOR PATENTS, WASHINGTON, DC 20231.

*William D Noonan*William D. Noonan, M.D.
Attorney for ApplicantPRELIMINARY AMENDMENTASSISTANT COMMISSIONER FOR PATENTS
WASHINGTON, DC 20231

Prior to calculating the fee for or examining the accompanying patent application, please enter the following amendments:

In the claims:

a¹ 9. A substantially pure DNA comprising (a) the [sequence of SEQ. I.D. NO. 1] DNA of claim 7 or (b) a degenerate variant thereof.

a² 14. A method of identifying a candidate compound which inhibits estrogen receptor (ER)-dependent transcription comprising contacting the compound with [an] the AIB1 polypeptide of claim 12 and determining whether the compound binds to the polypeptide, wherein binding of the compound to the polypeptide indicates that the compound inhibits ER-dependent transcription.

a³ 28. [A] The method of claim 22, further comprising a method of detecting breast cancer in a tissue sample, comprising determining the number of cellular copies of an AIB1 gene in the tissue sample, wherein an increase in the number of copies compared to the number of copies in a normal control tissue indicates the presence of a breast carcinoma.